

## Heterocycles. CXVIII. A Novel Method of Annulation of the 1,2,4-Triazole Ring of the N<sub>2</sub>-C<sub>3</sub> Bond to Azines<sup>1</sup>

S. Polanc, B. Verček, B. Šek, B. Stanovnik, and M. Tišler\*


Department of Chemistry, University of Ljubljana, 61000 Ljubljana, Yugoslavia

Received February 15, 1974

Several examples of formation of triazoloazines by a novel synthetic procedure are described. 2-Aminoazines were transformed into the corresponding *N,N*-dimethylaminomethyleneamino derivatives, which reacted with hydroxylamine to afford the hydroxyiminomethyleneamino compounds. In the presence of polyphosphoric acid, these were cyclized to give triazoloazines. Several other transformations involving these ring systems are described.


In a short communication we have described a new route to *s*-triazoloazines in which the triazole ring is fused to the azine ring through the N<sub>2</sub>-C<sub>3</sub> bond.<sup>2</sup> We wish now to report the details of this general synthetic method and its extension to several heterocyclic systems.

2-Aminoazines react readily with *N,N*-dimethylaminomethyl acetal to give the corresponding *N,N*-dimethylaminomethylene derivatives (2) (Table I). These reacted further with hydroxylamine with displacement of the dimethylamino group to give the corresponding hydroxyiminomethyleneamino derivatives (3 vs. 4)



(Table II). Besides hydroxylamine, *O*-methylhydroxylamine reacted similarly, whereas no reaction occurred with *N,O*-dimethylhydroxylamine. There are some reports concerning the hydroxyiminomethyleneamino compounds and their structure, *i.e.*, the possibility to exist either in the hydroxylamino or hydroxyimino form.<sup>3,4</sup> In the heterocyclic series such compounds result from the action of hydroxylamine on quinazoline, with cleavage of the pyrimidine ring,<sup>5</sup> and similar transformations were recorded in the case of 4-hydroxy-6-methylpteridine.<sup>6</sup> Nmr studies on our <sup>15</sup>N compounds revealed that these compounds are best represented as formamidoximes (4).<sup>7</sup> It was also shown that they exist in the anti (*Z*) form. This is certainly due to hydrogen bonding, since for the majority of aliphatic,<sup>8</sup> aromatic,<sup>9</sup> or six-membered heterocyclic<sup>10</sup> aldoximes the *E* configuration is thermodynamically more stable. They react with phenyl isocyanate to give the corresponding *O*-acylamino derivatives which are unstable.

With acetic anhydride or isopropenyl acetate dehydration took place and the oxime 4a (R<sub>1</sub> = H) was transformed into the known<sup>11</sup> 2-cyanoaminopyridine. However, treatment with polyphosphoric acid afforded in good yield the corresponding *s*-triazoloazines (5) (Table III). In this manner, at position 2 unsubstituted representatives of *s*-triazolo[1,5-*a*]pyridine (6), *s*-triazolo[1,5-*b*]pyridazine (7),<sup>12</sup> *s*-triazolo[1,5-*a*]pyrimidine (8), *s*-triazolo[1,5-*a*]pyra-




**Table I**  
**Dimethylaminomethyleneamino Heterocycles<sup>a</sup>**



Registry no.	Compd	Mp, °C	Crystallized from	Yield, %	Mass spectrum M <sup>+</sup>	Nmr spectrum, $\tau$
51519-06-3	<b>2a</b> , R <sub>1</sub> = NO <sub>2</sub>	159–160	Ethanol	98	194	DMSO- <i>d</i> <sub>6</sub> : 3.24 (d, H <sub>3</sub> ), 1.86 (dd, H <sub>4</sub> ), 1.13 (d, H <sub>6</sub> ), 1.42 (s, CH), 6.86 and 6.96 (s, NMe <sub>2</sub> ); $J_{3,4} = 9.0$ , $J_{4,6} = 3.0$ Hz
51519-07-4	<b>2b</b> , R <sub>1</sub> = H; R <sub>2</sub> = Me; R <sub>3</sub> = Cl	87	<i>n</i> -Hexane	82	198	CDCl <sub>3</sub> : 1.41 (s, N=CH), 2.99 (q, H <sub>6</sub> ), 6.90 and 6.92 (s, NMe <sub>2</sub> ), 7.71 (d, 5-Me); $J_{4,5-\text{Me}} = 0.7$ Hz
51519-08-5	<b>2b</b> , R <sub>1</sub> = R <sub>2</sub> = Me; R <sub>3</sub> = Cl	90	<i>n</i> -Hexane	82	212	CDCl <sub>3</sub> : 1.64 (s, CH), 6.92 (s, NMe <sub>2</sub> ), 7.71 (s, 4-, 5-Me)
6578-34-3	<b>2c</b> , R <sub>1</sub> = H	104–106	Chloroform and petroleum ether	93	150	DMSO- <i>d</i> <sub>6</sub> : 1.57 (d, H <sub>1</sub> and H <sub>6</sub> ), 3.15 (t, H <sub>5</sub> ), 1.45 (s, CH), 6.89 and 6.98 (s, NMe <sub>2</sub> ); $J_{4,5} = J_{5,6} = 5.0$ Hz
51567-39-6	<b>2c</b> , R <sub>1</sub> = Me		Distilled at 120–130° (2 mm)	90		CDCl <sub>3</sub> : 3.43 (s, H <sub>5</sub> ), 1.41 (s, CH), 7.63 (s, 4-, 6-Me), 6.87 and 6.91 (s, NMe <sub>2</sub> )
51519-09-6	<b>2d</b> , R <sub>1</sub> = R <sub>2</sub> = H		Distilled at 130–140° (5 mm)	92	150	CDCl <sub>3</sub> : 2.00 (s, H <sub>3</sub> ), 1.80 and 1.99 (d, H <sub>5</sub> and H <sub>6</sub> ), 1.64 (s, CH), 6.92 (s, NMe <sub>2</sub> ); $J_{5,6} = 1.0$ Hz
51519-10-9	<b>2d</b> , R <sub>1</sub> = Cl; R <sub>2</sub> = H	97–99	Ethyl acetate and petroleum ether	89	184 and 186	DMSO- <i>d</i> <sub>6</sub> : 1.72 and 2.03 (d, H <sub>3</sub> and H <sub>6</sub> ), 1.49 (s, CH), 6.89 and 6.98 (s, NMe <sub>2</sub> ); $J_{3,6} = 1.5$ Hz
51519-11-0	<b>2d</b> , R <sub>1</sub> = H; R <sub>2</sub> = Cl	60–62	Chloroform and <i>n</i> -hexane	87	184 and 186	CDCl <sub>3</sub> : 1.89 and 1.97 (s, H <sub>3</sub> and H <sub>6</sub> ), 1.55 (s, CH), 6.86 and 6.89 (s, NMe <sub>2</sub> )
51519-12-1	<b>2e</b> , R <sub>1</sub> = morpholino	203–205	Chloroform and <i>n</i> -hexane	93	321	CDCl <sub>3</sub> : 1.21 (s, CH), 6.88 (s, NMe <sub>2</sub> ), 6.23 (broad s, 4- and 6-morpholino group)
51519-13-2	<b>2g</b> , R <sub>1</sub> = Cl	172–173	Ethyl acetate	97	235 and 237	DMSO- <i>d</i> <sub>6</sub> : 0.63 (dd, H <sub>2</sub> ), 1.95 (dd, H <sub>3</sub> ), 1.15 (dd, H <sub>4</sub> ), 1.18 (s, CH), 6.68 and 6.75 (s, NMe <sub>2</sub> ); $J_{2,3} = 4.5$ , $J_{3,4} = 8.0$ , $J_{2,4} = 1.5$ Hz
51519-14-3	<b>2h</b> , R <sub>1</sub> = Cl	152–154	Chloroform and <i>n</i> -hexane	98	235 and 237	DMSO- <i>d</i> <sub>6</sub> : 0.62 (dd, H <sub>2</sub> ), 1.94 (dd, H <sub>3</sub> ), 1.43 (dd, H <sub>4</sub> ), 1.40 (s, CH), 6.74 and 6.79 (s, NMe <sub>2</sub> )

<sup>a</sup> Satisfactory analytical data were obtained for all compounds listed.

**Table II**  
**Hydroxyiminomethyleneamino Heterocycles<sup>a</sup>**



Registry no.	Compd	Mp, °C	Crystallized from	Yield %	Mass spectrum M <sup>+</sup>	Nmr spectrum, $\tau$
21881-75-4	<b>4a</b> , R <sub>1</sub> = NO <sub>2</sub>	218	Ethanol	90	182	DMF- <i>d</i> <sub>7</sub> : 2.75 (d, H <sub>3</sub> ), 1.68 (dd, H <sub>4</sub> ), 1.06 (d, H <sub>6</sub> ), 2.15 (deg. d, CH), -0.13 (broad, NH), -0.50 (broad, OH); $J_{3,4} = 9.5$ , $J_{4,6} = 3.0$ , $J_{\text{CHNH}} = 8.0$ Hz
51519-15-4	<b>4b</b> , R <sub>1</sub> = R <sub>2</sub> = H; R <sub>3</sub> = Cl	190–194	Methanol and diethyl ether	88	172	DMSO- <i>d</i> <sub>6</sub> : 2.40 and 2.65 (d, H <sub>4</sub> , H <sub>5</sub> ), 2.17 (d, CH), 0.27 (d, CHNH), -0.38 (s, OH); $J_{4,5} = 9.0$ , $J_{\text{CHNH}} = 10.5$ Hz
51519-16-5	<b>4b</b> , R <sub>1</sub> = H; R <sub>2</sub> = Me; R <sub>3</sub> = Cl	200–203	Methanol	97	186	DMSO- <i>d</i> <sub>6</sub> : 2.72 (s, H <sub>5</sub> ), 7.74 (s, 4-Me), 2.19 (d, CH), 0.47 (d, NH), -0.25 (s, OH); $J_{\text{NHCH}} = 9.2$ Hz
51519-17-6	<b>4b</b> , R <sub>1</sub> = R <sub>2</sub> = Me; R <sub>3</sub> = Cl	190	Methanol	87	200	DMSO- <i>d</i> <sub>6</sub> : 2.11 (s, CH), 7.69 and 7.76 (s, 4- and 5-Me), -0.41 (broad, NH and OH)
51519-18-7	<b>4c</b> , R <sub>1</sub> = H	198–200	Ethanol	88	138	DMSO- <i>d</i> <sub>6</sub> : 1.45 (d, H <sub>1</sub> and H <sub>6</sub> ), 3.00 (t, H <sub>5</sub> ), 2.17 (s, CH), 0.95 (broad, NH), -0.40 (broad, OH); $J_{4,5} = J_{5,6} = 5.0$ Hz
51519-19-8	<b>4c</b> , R <sub>1</sub> = Me	269–270	Methanol	90	166	DMSO- <i>d</i> <sub>6</sub> (124°): 3.39 (s, H <sub>6</sub> ), 2.34 (s, CH), 7.73 (s, 4- and 6-Me)
51519-20-1	<b>4d</b> , R <sub>1</sub> = R <sub>2</sub> = H	202–204	Ethanol	91	138	DMSO- <i>d</i> <sub>6</sub> : 1.53 (d, H <sub>3</sub> ), 1.85 (q, H <sub>5</sub> ), 1.95 (d, H <sub>6</sub> ), 2.20 (d, CH), 0.30 (d, NH), -0.25 (broad s, OH); $J_{5,6} = 3.0$ , $J_{3,6} = 1.0$ , $J_{\text{NHCH}} = 9.0$ Hz

Table II  
(Continued)

Registry no.	Compd	Mp, °C	Crystallized from	Yield %	Mass spectrum M <sup>+</sup>	Nmr spectrum, $\tau$
51519-21-2	4d, R <sub>1</sub> = Cl; R <sub>2</sub> = H	217-218	Methanol	80	172 and 174	DMSO- <i>d</i> <sub>6</sub> : 1.70 (s, H <sub>3</sub> and H <sub>6</sub> ), 2.25 (broad, CH), 0.05 (broad, NH), -0.40 (broad, OH)
51519-22-3	4d, R <sub>1</sub> = H; R <sub>2</sub> = Cl	214-216	Ethanol	76	172 and 174	DMSO- <i>d</i> <sub>6</sub> : 1.61 and 1.92 (s, H <sub>3</sub> and H <sub>6</sub> ), 2.38 (deg. d, CH), 0.05 (broad, NH), -0.50 (broad, OH); J <sub>NHCH</sub> = 2.0 Hz
51519-23-4	4e, R <sub>1</sub> = morpholino	238-242	Ethanol	71	309	DMSO- <i>d</i> <sub>6</sub> : 2.36 (d, CH), 6.40 (broad s, 4-, 6-morpholino), 1.86 (d, NH), -0.25 (s, OH); J <sub>NHCH</sub> = 10.5 Hz
51519-24-5	4f <sup>b</sup>	245-248	Water	81	178	DMSO- <i>d</i> <sub>6</sub> : 1.47 (s, H <sub>2</sub> ), 1.60 (d, H <sub>8</sub> ), 2.27 (d, H <sub>7</sub> ), 2.10 (d, CH), -0.78 (broad, OH), -0.11 (broad, NH); J <sub>7,8</sub> = 8.6, J <sub>CHNH</sub> = 9.0 Hz
51519-25-6	4g, R <sub>1</sub> = Cl	188-189	Methanol	65	223 and 225	DMSO- <i>d</i> <sub>6</sub> : 0.85 (dd, H <sub>2</sub> ), 2.08 (dd, H <sub>8</sub> ), 1.05 (dd, H <sub>4</sub> ), 2.02 (s, CH), 0.15 (broad, NH), -0.40 (broad, OH); J <sub>2,3</sub> = 4.5, J <sub>3,4</sub> = 8.0, J <sub>2,4</sub> = 1.5 Hz
51519-26-7	4h, R <sub>1</sub> = Cl	188-190	Methanol and <i>n</i> -hexane	79	223 and 225	DMSO- <i>d</i> <sub>6</sub> : 1.57 (dd, H <sub>2</sub> ), 1.99 (dd, H <sub>8</sub> ), 0.85 (dd, H <sub>2</sub> ), 1.98 (s, CH), -0.79 (s, OH), 0.85 (broad, NH); J <sub>2,3</sub> = 4.5, J <sub>2,4</sub> = 1.5, J <sub>3,4</sub> = 8.0 Hz

<sup>a</sup> Satisfactory analytical data were obtained for all compounds listed. <sup>b</sup> Obtained after 4 hr under reflux.

Table III  
*s*-Triazoloazines<sup>a</sup>

Registry no.	Compd	Mp, °C	Crystallized from	Yield, %	Mass spectrum, M <sup>+</sup>	Nmr spectrum, $\tau$
31040-14-9	6, R = NO <sub>2</sub>	204-208 <sup>b</sup>	Ethanol	61	164	<i>c</i>
42399-79-1	7, R = Cl; R <sub>1</sub> = R <sub>2</sub> = H	135-138	Ethanol	67	154	<i>c</i>
51519-27-8	7, R = Cl; R <sub>1</sub> = Me; R <sub>2</sub> = H	138-142	Water	78	168	CDCl <sub>3</sub> : 1.66 (s, H <sub>2</sub> ), 2.11 (q, H <sub>8</sub> ), 7.47 (d, 7-Me); J <sub>8,7-Me</sub> = 1.2 Hz
51519-28-9	7, R = Cl; R <sub>1</sub> = R <sub>2</sub> = Me	108-110	Water	88	182	CDCl <sub>3</sub> : 1.70 (s, H <sub>2</sub> ), 7.30 and 7.52 (s, 7- and 8-Me)
275-02-5	8, R = H	140-141 <sup>d</sup>		82	120	<i>c</i>
7681-99-4	8, R = Me	135-137 <sup>e</sup>	Ethanol	81	148	CDCl <sub>3</sub> : 1.41 (s, H <sub>2</sub> ), 2.99 (s, H <sub>6</sub> ), 7.13 and 7.28 (s, 5- and 7-Me)
399-66-6	9, R = R <sub>1</sub> = H	127	Ethanol	70	120	<i>c</i>
42399-82-6	9, R = Cl; R <sub>1</sub> = H	108-110	Ethanol	61	154 and 156	<i>c</i>
51519-29-0	9, R = H; R <sub>1</sub> = Cl	140-141	Ethanol	76	154 and 156	DMSO- <i>d</i> <sub>6</sub> : 1.30 (s, H <sub>2</sub> ), 0.75 (d, H <sub>8</sub> ), 0.55 (d, H <sub>8</sub> ); J <sub>5,8</sub> = 1.5 Hz
42399-84-8	10, R = morpholino	218-222	Ethanol	70	291	<i>c</i>
51519-30-3	11, R = Cl	218-220	Ethanol	71	205 and 207	CDCl <sub>3</sub> : 1.64 (s, H <sub>2</sub> ), 0.81 (dd, H <sub>8</sub> ), 2.12 (dd, H <sub>9</sub> ), 1.14 (dd, H <sub>10</sub> ); J <sub>8,9</sub> = 4.5, J <sub>9,10</sub> = 8.0, J <sub>8,10</sub> = 1.5 Hz
51519-31-4	12, R = Cl	224-226	Ethanol	54	205 and 207	DMSO- <i>d</i> <sub>6</sub> : 1.38 (s, H <sub>2</sub> ), 1.33 (dd, H <sub>7</sub> ), 2.03 (dd, H <sub>8</sub> ), 0.73 (dd, H <sub>9</sub> ); J <sub>7,8</sub> = 8.0, J <sub>7,9</sub> = 1.5, J <sub>8,9</sub> = 4.5 Hz
51519-32-5	14	208-212	Chloroform and <i>n</i> -hexane	67	160	DMSO- <i>d</i> <sub>6</sub> : 1.36 (s, H <sub>2</sub> , H <sub>7</sub> ), 1.38 (s, H <sub>4</sub> , H <sub>5</sub> )

<sup>a</sup> Satisfactory analytical data were obtained for all compounds listed. <sup>b</sup> Lit.<sup>27</sup> mp 207°. <sup>c</sup> See ref 2. <sup>d</sup> Lit.<sup>28</sup> mp 140-142°. <sup>e</sup> Lit.<sup>29</sup> mp 136-137°.

zine (9), *s*-triazolo[1,5-*a*]-1,3,5-triazine (10), pyrido[3,2-*d*]-*s*-triazolo[1,5-*b*]pyridazine (11), and the isomeric pyrido[2,3-*d*]-*s*-triazolo[1,5-*b*]pyridazine (12), *s*-triazolo[4,3-*b*]-*s*-triazolo[5',1'-*f*]pyridazine (13) and bis-*s*-triazolo[1,5-*b*:5',1'-*f*]pyridazine (14) have been prepared. The last four are new heterocyclic systems.

*s*-Triazolo[1,5-*a*]pyridines (6) have previously been prepared by oxidative cyclization of 2-pyridylamidines.<sup>13</sup> Most of the methyl-substituted 2-hydroxyiminomethyl-

leneaminopyridines (4d) did not cyclize in the presence of polyphosphoric acid. The corresponding oxime derived from 2-aminopyridine was transformed under the same experimental conditions into *N*-pyridyl-2-urea,<sup>14</sup> indicating that Beckmann rearrangement took place. In an attempt to cyclize the oxime 4a (R<sub>1</sub> = H) with lead tetraacetate, 2-cyanoaminopyridine was isolated, whereas the same reaction on 2-methoxyiminomethyleneaminopyridine afforded methyl *N*-(pyridyl-2)-carbamate.<sup>15</sup> A successful



synthesis of the parent compound (6, R = H) was achieved by irradiation ( $\lambda$  254 nm, 10 hr) of a methanolic solution of 4a (R<sub>1</sub> = H). As by-products 2-aminopyridine and 2-formylaminopyridine were formed and separated by glc.

In the pyridazine series no difficulties were encountered. Although we have recently described<sup>16</sup> a synthesis of *s*-triazolo[1,5-*b*]pyridazines (7), 2-unsubstituted derivatives could not be obtained by this method. The cyclization of the corresponding oximes could be extended to build two tricyclic systems (13 and 14). Several reactions have been investigated on the bicyclic system and nucleophilic substitutions proceeded as anticipated. The chlorine atom of 6-chloro-*s*-triazolo[1,5-*b*]pyridazine is replaceable and the corresponding 6-amino (7, R = NH<sub>2</sub>; R<sub>1</sub> = R<sub>2</sub> = H), 6-hydrazino (7, R = NHNH<sub>2</sub>; R<sub>1</sub> = R<sub>2</sub> = H), 6-oxo (15, X = O; R = H), 6-thiono (15, R = H; X = S) or 6-methoxy (7, R = OMe; R<sub>1</sub> = R<sub>2</sub> = H) compounds were thus prepared. The 6-azido compound (7, R = N<sub>3</sub>; R<sub>1</sub> = R<sub>2</sub> = H) could be prepared either from the corresponding 6-hydrazino compound by nitrosation or from the substituted tetrazolo[1,5-*b*]pyridazine (17) by simultaneous formation of the triazole ring and tetrazolo-azido isomerization, as previously applied to related systems.<sup>17</sup> The azido compound reacted with diethylamine to give 6-diethylaminomethyleneamino compound (7, R = Et<sub>2</sub>NCH=N-; R<sub>1</sub> = R<sub>2</sub> = H). This is another example of this unusual reaction which we have discovered recently.<sup>18</sup> Moreover, the azido compound reacted with acetylacetone to give the cycloaddition product (18) in accordance with our observations on related systems.<sup>19</sup> Methylation of the 6-oxo compound (15, R = H; X = O) afforded a mixture of the 6-methoxy (7, R = OMe; R<sub>1</sub> = R<sub>2</sub> = H) and *N*-methyl derivative (15, R = Me; X = O). Chlorination of 6-chloro-*s*-triazolo[1,5-*b*]pyridazine with phosphorus pentachloride afforded the trichloro compound (7, R = R<sub>1</sub> = R<sub>2</sub> = Cl), position 2 of the bicyclic system remaining unaffected. The chlorine atoms at position 6 and 8 of the trichloro compound reacted readily with sodium methoxide, but the most reactive is that at position 8 as evidenced from the reaction with dimethylamine which gave the monosubstitution product (7, R = R<sub>1</sub> = Cl; R<sub>2</sub> = NMe<sub>2</sub>). Hydrogenolysis over palladium afforded the dehalogenated products, except in the case of 6-chloro-*s*-triazolo[1,5-*b*]pyridazine, which was transformed into 5,6,7,8-tetrahydro-*s*-triazolo[1,5-*b*]pyridazine with simultaneous dehalogenation and reduction of the pyridazine part. On the other hand, hydrazinolysis of the parent compound cleaved the six-membered ring and recyclization afforded the pyrazolyltriazole (16). Similar transformations we have observed with some of the related heterocyclic system.<sup>20,21</sup>

The *s*-triazolo[1,5-*a*]pyridazine system (9) has been reported only once,<sup>22</sup> and the synthetic approach described provides only 2-substituted compounds. 2-Unsubstituted *s*-triazolo[1,5-*a*]pyridazines are now readily available by this new method from the appropriate 2-aminopyridazines. Many reactions involving this system will be dealt with in another report.

**Acknowledgment.** The authors wish to thank Dr. M. Japelj, Krka pharmaceutical works, Novo mesto, for the performance of some elemental analyses.

**Registry No.**—2f, 51519-33-6; 4b (R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = H), 51519-34-7; 7 (R = R<sub>1</sub> = R<sub>2</sub> = H), 40369-38-8; 7 (R = NH<sub>2</sub>; R<sub>1</sub> = R<sub>2</sub> = H), 51519-35-8; 7 (R = NHNH<sub>2</sub>; R<sub>1</sub> = R<sub>2</sub> = H), 51519-36-9; 7 (R = NHN=CMe<sub>2</sub>; R<sub>1</sub> = R<sub>2</sub> = H), 51519-37-0; 7 (R = NHN=CPh; R<sub>1</sub> = R<sub>2</sub> = H), 51519-38-1; 7 (R = NHN=CHMe; R<sub>1</sub> = R<sub>2</sub> = H), 51519-39-2; 7 (R = N<sub>3</sub>; R<sub>1</sub> = R<sub>2</sub> = H), 42399-80-4; 7 (R = Et<sub>2</sub>NCH=N-; R<sub>1</sub> = R<sub>2</sub> = H), 51519-40-5; 7 (R = OMe; R<sub>1</sub> = R<sub>2</sub> = H), 51519-41-6; 7 (R = SMe; R<sub>1</sub> = R<sub>2</sub> = H), 51519-42-7; 7 (R = R<sub>1</sub> = R<sub>2</sub> = Cl), 51519-43-8; 7 (R = R<sub>2</sub> = OMe; R<sub>1</sub> = Cl), 51519-44-9; 7 (R = R<sub>2</sub> = OMe; R<sub>1</sub> = H), 51519-45-0; 7 (R = R<sub>2</sub> = H; R<sub>1</sub> = Me), 51519-46-1; 7 (R = H; R<sub>1</sub> = R<sub>2</sub> = Me), 51519-47-2; 7 (R = R<sub>1</sub> = Cl; R<sub>2</sub> = NMe<sub>2</sub>), 51519-48-3; 7 (R = R<sub>1</sub> = H; R<sub>2</sub> = NMe<sub>2</sub>), 51519-49-4; 13 (R = Me), 51519-50-7; 13 (R = Ph), 51519-51-8; 15 (R = H; X = O), 51519-52-9; 15 (R = Me, X = O), 51519-53-0; 15 (R = H, X = S), 51519-54-1; 16, 51519-55-2; 17, 42489-25-8; 18, 51519-56-3; 6-amino-*s*-triazolo[1,5-*b*]pyridazine, 51519-35-8; *N,N*-dimethylformamide dimethyl acetal, 4637-24-5; *N,N*-dimethyl-7-(pyridazinyl-3)formamidine, 35053-54-4; 6-acetamidotetrazolo[1,5-*b*]pyridazine, 51519-57-4; 5,6,7,8-tetrahydro-*s*-triazolo[1,5-*b*]pyridazine, 51519-58-5.

**Miniprint Material Available.** Full-sized photocopies of the miniprinted material from this paper only or microfiche (105 × 148 mm, 24× reduction, negatives) containing all of the miniprinted and supplementary material for the papers in this issue may be obtained from the Journals Department, American Chemical Society, 1155 16th St., N.W., Washington, D. C. 20036. Remit check or money order for \$3.00 for photocopy or \$2.00 for microfiche, referring to code number JOC-74-2143.

## References and Notes

- Pyridazines, Part LXVI.
- S. Polanc, B. Verček, B. Stanovnik, and M. Tišler, *Tetrahedron Lett.*, 1677 (1973).
- N. E. Alexandrou and D. N. Nicolaides, *Org. Magn. Resonance*, **4**, 229 (1972).
- N. E. Alexandrou and D. N. Nicolaides, *Org. Magn. Resonance*, **4**, 591 (1972).
- K. Adachi, *Chem. Pharm. Bull.*, **7**, 479 (1959).
- J. Clark and G. Neath, *J. Chem. Soc. C*, 919 (1968).
- S. Polanc, B. Verček, B. Stanovnik, and M. Tišler, *J. Heterocycl. Chem.*, **11**, 103 (1974).
- G. J. Karabatsos and R. A. Taller, *Tetrahedron*, **24**, 3347 (1968).
- G. Westmark, *Svensk. Kem. Tidskr.*, **79**, 249 (1967).
- E. J. Poziomek and L. G. Vaughan, *J. Pharm. Sci.*, **54**, 811 (1965).
- R. Charonnat and F. Le Perdriel, *Ann. Pharm. Fr.*, **26**, 469 (1968); *Chem. Abstr.*, **70**, 37615 (1969).
- A referee suggested this naming instead of *s*-triazolo[2,3-*b*]pyridazine as used previously.<sup>2</sup>
- J. D. Bower and G. R. Ramage, *J. Chem. Soc.*, 4506 (1957).
- M. P. Gerchuk and S. Z. Taits, *Zh. Obshch. Khim.*, **20**, 910 (1950); *Chem. Abstr.*, **44**, 9443 (1950).
- R. L. Shriner and R. G. Child, *J. Amer. Chem. Soc.*, **74**, 549 (1952).
- M. Zupan, B. Stanovnik, and M. Tišler, *Tetrahedron Lett.*, 4179 (1972).
- For review see M. Tišler, *Synthesis*, 123 (1973).
- S. Polanc, B. Stanovnik, and M. Tišler, *J. Heterocycl. Chem.*, **10**, 565 (1973).
- A. Gorup, M. Kovačič, B. Kranjc-Škraba, B. Mihelčič, S. Simonič, B. Stanovnik, and M. Tišler, *Tetrahedron*, in press.
- A. Bezeg, B. Stanovnik, B. Šket, and M. Tišler, *J. Heterocycl. Chem.*, **9**, 1171 (1972).
- A. Pollak, S. Polanc, B. Stanovnik, and M. Tišler, *Monatsh. Chem.*, **103**, 1591 (1972).
- T. Okamoto, Y. Torigoe, M. Sato, and Y. Isogai, *Chem. Pharm. Bull.*, **16**, 1154 (1968).
- L. Bernardi, G. Palamidessi, A. Leone, and G. Larini, *Gazz. Chim. Ital.*, **91**, 1431 (1961).
- J. B. Bickling, J. W. Mason, O. W. Woltersdorf, J. H. Jones, S. F. Kwong, C. M. Robb, and E. J. Cragoe, *J. Med. Chem.*, **8**, 638 (1965).
- G. Palamidessi and L. Bernardi, *J. Org. Chem.*, **29**, 2491 (1964).
- M. Zupan, B. Stanovnik, and M. Tišler, *J. Org. Chem.*, **37**, 2960 (1972).
- K. T. Potts and C. R. Surapaneni, *J. Heterocycl. Chem.*, **7**, 1019 (1970).
- C. F. H. Allen, H. R. Beilfuss, D. M. Burness, G. A. Reynolds, J. F. Tinker, and J. A. Van Allan, *J. Org. Chem.*, **24**, 796 (1959).
- J. A. Bee and F. L. Rose, *J. Chem. Soc.*, 2031 (1966).